- Home
- REGN vs USB Comparison
REGN vs USB Comparison
Compare REGN & USB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REGN | USB |
|---|---|---|
| Founded | 1988 | 1863 |
| Country | United States | United States |
| Employees | N/A | 68520 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.2B | 85.1B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | REGN | USB |
|---|---|---|
| Price | $638.39 | $55.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 19 |
| Target Price | ★ $830.16 | $60.28 |
| AVG Volume (30 Days) | 1.0M | ★ 6.9M |
| Earning Date | 04-29-2026 | 04-16-2026 |
| Dividend Yield | 0.55% | ★ 3.70% |
| EPS Growth | ★ 8.19 | N/A |
| EPS | ★ 6.75 | N/A |
| Revenue | ★ $5,872,227,000.00 | N/A |
| Revenue This Year | $12.45 | $16.09 |
| Revenue Next Year | $10.13 | $5.36 |
| P/E Ratio | $93.13 | ★ $12.72 |
| Revenue Growth | ★ 20.82 | N/A |
| 52 Week Low | $494.42 | $42.55 |
| 52 Week High | $821.11 | $61.19 |
Technical Indicators
Market Signals| Indicator | REGN | USB |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 54.61 |
| Support Level | $610.60 | $55.40 |
| Resistance Level | $783.87 | $55.88 |
| Average True Range (ATR) | 15.40 | 1.05 |
| MACD | 1.54 | 0.11 |
| Stochastic Oscillator | 80.31 | 87.41 |
Price Performance
Historical ComparisonAbout REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
About USB U.S. Bancorp
With assets of around $700 billion, U.S. Bancorp is one of the largest regional banks in the US with its footprint in 26 states. The bank's branch network is mostly in Midwestern and Western markets. U.S. Bancorp has a comprehensive product set, with offerings in retail and commercial banking, credit cards, mortgages, payment services, trust, wealth, and capital market services.